Your search for non small cell lung cancer returned 45 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove

Your search for non small cell lung cancer returned 45 results

Sort Results:

Relevant Recent
News

Tecentriq Approved for Non-Small Cell Lung Cancer

Genentech announced that the Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities.
Drugs in the Pipeline

PARP Inhibitor Veliparib Gets Orphan Drug Status from FDA

AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an investigational combination with chemotherapies or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
News

Companion Dx Test for Iressa Receives Marketing Approval

Qiagen announced that it has received marketing approval for its therascreen EFGR RGQ PCR Kit as a companion diagnostic to Iressa (geftinib; AstraZeneca) for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).
Drugs in the Pipeline

sNDA Accepted, Priority Review Granted to Tarceva for Genetically Distinct NSCLC

Astellas announced that the FDA has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations; the application has been granted Priority Review status.